Clinical perspectives of PSMA PET/MRI for prostate cancer

Clinical perspectives of PSMA PET/MRI for prostate cancer

Prostate cancer imaging has become an important diagnostic modality for tumor evaluation. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has been extensively studied, and the results are robust and promising. The advent of the PET/magnetic resonance imaging (MRI) has ad...

Full description

Bibliographic Details
Main Authors:	Felipe de Galiza Barbosa, Marcelo Araújo Queiroz, Rafael Fernandes Nunes, José Flávio Gomes Marin, Carlos Alberto Buchpiguel, Giovanni Guido Cerri
Format:	Article
Language:	English
Published:	Faculdade de Medicina / USP 2018-09-01
Series:	Clinics
Subjects:	Prostate Cancer Positron Emission Tomography/Magnetic Resonance Imaging Diagnostic Imaging Tumor Staging Local Neoplasm Recurrence
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322018000200325&lng=en&tlng=en

Similar Items

Is there the role of 18F-choline PET/CT in prostate cancer patients?
by: Hodolič Marina
Published: (2012-01-01)

Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings
by: Felipe de Galiza Barbosa, et al.
Published: (2020-03-01)

A prospective study on dual time 18F-FDG-PET/CT in high-risk prostate cancer patients
by: Mike Allan Mortensen, et al.
Published: (2018-12-01)

Positron emission tomography/magnetic resonance imaging (PET/MRI): An update and initial experience at HC-FMUSP
by: Marcelo A. Queiroz, et al.

Application Progress of 68Ga-PSMA PET/CT in Recurrent Prostate Cancer
by: YANG Liping, et al.
Published: (2018-07-01)

11C-Choline PET/CT and PSA kinetics
by: Castellucci Paolo, et al.
Published: (2012-01-01)

68Ga-PSMA PET/CT versus CT and bone scan for investigation of PSA failure post radical prostatectomy
by: Yuigi Yuminaga, et al.
Published: (2021-04-01)

Performance of Ga-68 PSMA PET/CT for diagnosis and grading of local prostate cancer
by: Timothy N. Kwan, et al.
Published: (2021-06-01)

PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review
by: Lars J. Petersen, et al.
Published: (2020-01-01)

PET-CT in oncology
by: Purandare N, et al.
Published: (2010-01-01)

Impact of 68GA-PSMA PET / CT on treatment of patients with recurrent / metastatic high risk prostate cancer - a multicenter study
by: Aline B. Mattiolli, et al.

Restaging the Biochemical Recurrence of Prostate Cancer with [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT: Diagnostic Performance and Impact on Patient Disease Management
by: Aloÿse Fourquet, et al.
Published: (2021-03-01)

Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?
by: Publio Cesar Cavalcanti Viana, et al.

Detection of Recurrent Prostate Cancer With 18F-Fluciclovine PET/MRI
by: Kirsten Margrete Selnæs, et al.
Published: (2020-12-01)

Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis
by: Sungmin Woo, et al.
Published: (2020-09-01)

Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer
by: Spencer T. Lake, et al.
Published: (2017-09-01)

In Vivo Molecular MRI Imaging of Prostate Cancer by Targeting PSMA with Polypeptide-Labeled Superparamagnetic Iron Oxide Nanoparticles
by: Yunkai Zhu, et al.
Published: (2015-04-01)

Evolution of prostate MRI: from multiparametric standard to less-is-better and different-is better strategies
by: Rossano Girometti, et al.
Published: (2019-01-01)

External Validation of Two Nomograms Developed for 68Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer 18F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible?
by: Henk B. Luiting, et al.
Published: (2021-06-01)

Potential of asphericity as a novel diagnostic parameter in the evaluation of patients with 68Ga-PSMA-HBED-CC PET-positive prostate cancer lesions
by: Sebastian Meißner, et al.
Published: (2017-10-01)

Micro-Ultrasound: a way to bring imaging for prostate cancer back to urology
by: Niklas Harland, et al.
Published: (2021-06-01)

Pitfalls of FDG-PET in the prostate for the surgical oncologist
by: Ellen O'Connor, et al.
Published: (2020-11-01)

Enhancing PSMA-uptake with androgen deprivation therapy – a new way to detect prostate cancer metastases?
by: Conrad Leitsmann, et al.

Updates of prostate cancer staging: Prostate-specific membrane antigen
by: Niranjan J Sathianathen, et al.
Published: (2016-12-01)

Inflammation appears as high Prostate Imaging–Reporting and Data System scores on prostate magnetic resonance imaging (MRI) leading to false positive MRI fusion biopsy
by: Elizabeth Rourke, et al.
Published: (2019-09-01)

Comparison between 68Ga-PSMA-11 PET/CT and multiparametric magnetic resonance imaging in patients with biochemically recurrent prostate cancer following robot-assisted radical prostatectomy
by: Jing-Ren Tseng, et al.
Published: (2021-01-01)

68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends
by: Cristian Udovicich, et al.
Published: (2017-12-01)

Prostate MRI: a national survey of Urologist’s attitudes and perceptions
by: Brandon J. Manley, et al.
Published: (2016-06-01)

The Use of MRI and PET Imaging Studies for Prostate Cancer Management: Brief Update, Clinical Recommendations, and Technological Limitations
by: Margaret Mansbridge, et al.
Published: (2019-08-01)

Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate Cancer
by: Wajahat Khatri, et al.
Published: (2021-04-01)

Prognostic value of subclassification (pT2 stage) of pathologically organ-confined prostate cancer: Confirmation of the changes introduced in the 8th edition of the American Joint Committee on Cancer (AJCC) staging system
by: Hugo Pontes Antunes, et al.
Published: (2018-09-01)

Dramatic polarization in genitourinary expert opinions regarding the clinical utility of positron emission tomography (PET) imaging in prostate cancer
by: Kiri A. Sandler, et al.

Peripheral ganglia in healthy rats as target structures for the evaluation of PSMA imaging agents
by: Heike Endepols, et al.
Published: (2019-06-01)

Clinical Utility of 18F-PSMA-1007 Positron Emission Tomography/Magnetic Resonance Imaging in Prostate Cancer: A Single-Center Experience
by: Ao Liu, et al.
Published: (2021-02-01)

PET/CT in renal and bladder cancers
by: Balenović Antonija, et al.
Published: (2012-01-01)

Prostate cancer detection using multiparametric 3 – tesla MRI and fusion biopsy: preliminary results
by: Thais Caldara Mussi, et al.

PET/CT in thyroid carcinoma
by: Mihailović Jasna
Published: (2012-01-01)

Predicting biochemical recurrence in patients with high-risk prostate cancer using the apparent diffusion coefficient of magnetic resonance imaging
by: Min Young Yoon, et al.
Published: (2017-01-01)

F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review
by: Schröer-Günther Milly A, et al.
Published: (2012-12-01)

Changes of Radiation Treatment Concept Based on 68Ga-PSMA-11-PET/CT in Early PSA-Recurrences After Radical Prostatectomy
by: Dirk Bottke, et al.
Published: (2021-06-01)